MAIA

SEC source: 0001878313-25-000054 · form4.xml · nonDerivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,628

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1147 to $1.1192, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001878313-25-000059 · form4a.xml · nonDerivative · entry 2

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 903,421

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1283 to $1.1416, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F3 · balance_after: The original Form 4 filed on December 1, 2025 had the incorrect total share balance owned by Vlad Vitoc. This Amended Form 4 is now reflecting the correct share balance owned.

SEC source: 0001878313-25-000056 · form4.xml · nonDerivative · entry 2

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 853,421

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.0145 to $1.0587, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001878313-25-000054 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 419,483

SEC source: 0001878313-25-000052 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,364,289

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.051, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000059 · form4a.xml · nonDerivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 853,421

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.0145 to $1.0587, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001878313-25-000045 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,349,289

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9550 to $1.05, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000047 · form4.xml · nonDerivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 831,421

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9606 to $0.9745, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001878313-25-000050 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 399,483

SEC source: 0001878313-25-000060 · form4a.xml · nonDerivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 831,421

SEC source: 0001878313-25-000040 · form4.xml · nonDerivative · entry 2

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 820,921

SEC source: 0001878313-25-000045 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,334,289

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9675 to $0.9899, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000040 · form4.xml · nonDerivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 810,921

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9128 to $0.9235, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001878313-25-000037 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 24,844

Underlying: Common Stock · 24,844 shares

Expires 2035-10-02

F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000035 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,459

Underlying: Common Stock · 20,459 shares

Expires 2035-10-02

F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-25-000033 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,434

Underlying: Common Stock · 21,434 shares

Expires 2035-10-02

F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-25-000031 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,331

Underlying: Common Stock · 25,331 shares

Expires 2035-10-02

F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-25-000029 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,459

Underlying: Common Stock · 20,459 shares

Expires 2035-10-02

F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-25-000027 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,946

Underlying: Common Stock · 20,946 shares

Expires 2035-10-02

F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-25-000019 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 19,230

Underlying: Common Stock · 19,230 shares

Expires 2028-10-01

F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on October 1, 2025. The options are exercisable beginning on the six-month anniversary of the issuance date and expire 3-years after the initial issuance date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000019 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,324,289

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on October 1, 2025

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-018658 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,380

Underlying: Common Stock · 20,380 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-018656 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,865

Underlying: Common Stock · 20,865 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-018655 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,232

Underlying: Common Stock · 25,232 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-018653 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 24,747

Underlying: Common Stock · 24,747 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-018651 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,350

Underlying: Common Stock · 21,350 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-018648 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,380

Underlying: Common Stock · 20,380 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-016869 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 33,333

Underlying: Common Stock · 33,333 shares

Expires 2030-06-03

F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on June 3, 2025. The options are exercisable beginning on the six-month anniversary of the issuance date and expire 5-years after the initial issuance date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust dated 1993.

SEC source: 0001127602-25-016869 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,305,059

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on June 3, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-014669 · form4.xml · derivative · entry 1

Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The stock options, granted on May 14, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-25-014670 · form4.xml · derivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The stock options, granted on May 14, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-25-014667 · form4.xml · derivative · entry 1

Himmelreich Jeffrey C · CIK 0002001189 · Head of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The stock options, granted on May 14, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-25-013965 · form4.xml · derivative · entry 2

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-05-08

F2 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on May 8, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.

SEC source: 0001127602-25-013965 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 588,218

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on May 8, 2025.

SEC source: 0001127602-25-013963 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 66,666

Underlying: Common Stock · 66,666 shares

Expires 2031-05-08

F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on May 8, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-013963 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,271,726

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on March 8, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-011819 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 24,800

Underlying: Common Stock · 24,800 shares

Expires 2035-04-04

F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are benefically owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-011817 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,667

Underlying: Common Stock · 20,667 shares

Expires 2035-04-04

F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-011815 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,291

Underlying: Common Stock · 20,291 shares

Expires 2035-04-04

F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-011813 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,304

Underlying: Common Stock · 26,304 shares

Expires 2035-04-04

F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-011811 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,042

Underlying: Common Stock · 21,042 shares

Expires 2035-04-04

F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-011809 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,291

Underlying: Common Stock · 20,291 shares

Expires 2035-04-04

F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-008330 · form4.xml · derivative · entry 2

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,333

Underlying: Common Stock · 33,333 shares

Expires 2031-03-03

F2 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on March 3, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.

SEC source: 0001127602-25-008330 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 568,218

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on March 3, 2025.

SEC source: 0001127602-25-008327 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-03-03

F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on March 3, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-008327 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,205,060

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on March 3, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-006578 · form4.xml · derivative · entry 2

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,333

Underlying: Common Stock · 73,333 shares

Expires 2030-08-24

F2 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

SEC source: 0001127602-25-006578 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 534,885

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were isused under the Issuer's 2021 Equity Incentive Plan on February 24, 2024.

SEC source: 0001127602-25-006574 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-08-24

F3 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on February 24, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-006574 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,180,060

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2024.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.